




# PHARMACEUTICAL 2020

## ALPINE IMMUNE SCIENCES INC. Rank 230 of 358





RealRate

# PHARMACEUTICAL 2020

## ALPINE IMMUNE SCIENCES INC. Rank 230 of 358



The relative strengths and weaknesses of ALPINE IMMUNE SCIENCES INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ALPINE IMMUNE SCIENCES INC. compared to the market average is the variable Other Liabilities, increasing the Economic Capital Ratio by 21% points. The greatest weakness of ALPINE IMMUNE SCIENCES INC. is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 58% points.

The company's Economic Capital Ratio, given in the ranking table, is 22%, being 14% points below the market average of 36%.

Input Variable	Value in 1000 USD
Assets, Current	42,302
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	8,681
Liabilities, Non-Current	15,938
Other Assets	10,239
Other Compr. Net Income	23
Other Expenses	338
Other Liabilities	0
Other Net Income	1,248
Other Revenues	2,552
Property and Equipment	1,552
Research and Development	35,847
Selling, General and Administrative Expense	9,467

Output Variable	Value in 1000 USD
Assets	54,093
Liabilities	24,619
Expenses	45,652
Revenues	2,552
Stockholders Equity	29,474
Net Income	-41,852
Comprehensive Net Income	-41,840
Economic Capital Ratio	22%